Temperature-sensitive Ovarian Carcinoma Cell Line (OvBH-1)

SKU:BHC10902061
—
Suppliers
Applied Biological Materials (abm) Inc.
Applied Biological Materials (abm) Inc.
Details Products
Overview
Click light‑blue chips for details
Temperature-sensitive Ovarian Carcinoma Cell Line (OvBH-1) is supplied as frozen tumor cell line derived from human ovary with adherent, epithelial growth properties. Commonly used in cancer biology, phenotype comparison, and response profiling under defined culture conditions.
Species Human
Cell Type Cell Lines, Tumor Cell Lines
Tissue Ovary
Growth Adherent, epithelial
Format Frozen
Options selector
Catalog no. Pack Size
T8163 1x106 cells / 1.0 ml
Available Options

Select the variant that best fits your experiment. Availability and lead time may vary by option.

  • Options: Pack Size: 1x106 cells / 1.0 ml
  • Lead time: varies by selected option; please contact us for current fulfillment timing.
  • Storage: Vapor phase of liquid nitrogen, or below -130°C.
  • Shipping: Ship with dry ice.
  • Upon receipt: store at the recommended temperature as soon as possible.
  • Sales terms and conditions: Please review prior to ordering.
Field Specification
Organism Human (H. sapiens)
Applications
  • Cell Culture (Growth)
  • Cell Viability
Tissue
  • Ovary
Disease Adenocarcinoma
Age 49 years old
Sex Female
Ethnicity Caucasian
Growth properties
  • Adherent
  • epithelial
Biosafety level BSL-2
Product format Frozen
Storage Vapor phase of liquid nitrogen, or below -130°C. Visually examine the packaging containers for signs of leakage or breakage. Immediately transfer frozen cells from dry ice packaging to a temperature below -130°C, preferably in liquid nitrogen vapor phase storage, until ready for use. To ensure the highest level of viability, thaw the vial and initiate culture as soon as possible upon receipt. If continued storage is desired, the vial should only be stored below -130°C or in liquid nitrogen vapor phase. Do not store at -70°C, as it will result in loss of viability. Cryopreservation: We recommend using serum-free CryoGuard™ Freezing Media (TM078) or, if serum is preferred, Cryopreservation Medium (TM024). We recommend using serum-free CryoGuard™ Freezing Media (TM078) or, if serum is preferred, Cryopreservation Medium (TM024).
Shipping Ship with dry ice.
Catalog no. (Mfr.) T8163
Main SKU BHC10902061

Overview

Cells were isolated from an ascitic fluid patient with an ovarian tumor histopathologically classified as ovarian clear cell adenocarcinoma, poorly differentiated (G3) and in stage FIGO IV. OvBH-1 cell showed expression of cytokeratins (CK): CK1,5,6,8,10,14,18,7,16/18, alongside vimentin, tumor-associated antigens (CA125, OV-TL3), p53 protein, c-rebB-2 oncoprotein detected by IHC.

Key elements and design rationale

  • Model identity: Temperature-sensitive Ovarian Carcinoma Cell Line (OvBH-1) is supplied as a tumor cell line derived from Human ovary.
  • Growth properties: Adherent, epithelial
  • Growth conditions: PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. Prigrow VIII Medium (TM018) + 10% FBS(Regular*) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂. *Do not heat-inactivate
  • Product format: Frozen, BSL-2

This cell-based model is generally used in cancer biology, phenotype comparison, and response profiling studies. Donor/background information is available for contextual interpretation.

Biological background

Sequencing of all coding exons of TP53 gene showed a natural genetic polymorphism namely a G-to-A substitution at nucleotide 13 432 GAG to GAA, corresponding to codon 2233 in exon 6.OvBH-1 cells are notable for their cytomorphological diversity and present two morphologically distinct cell types. The dominant cell type within the OVBH-1 line appears to have frank malignancy features, suggesting a more aggressive cancer phenotype. The epithelial origin of both cell types is confirmed by immunophenotypic staining using antibodies against different cytokeratins. The expression of tumor-associated antigens (CA125, OP-TL3) was found in both cell subtypes, reaffirming their origin from ovarian carcinoma. The OvBH-1 cell line has temperature-sensitive properties. This cell line is suitable for investigating the biological changes that contribute to carcinogenesis and chemoresistance. Donor/background information provided for this product: Female, 49, Caucasian, Adenocarcinoma.

Research relevance and current trends

  • Cell-line models continue to be used for tumor phenotype comparison, pathway perturbation studies, and assay development in controlled in vitro systems.
  • Engineered and subtype-defined tumor lines are often used to compare growth behavior, reporter output, and response patterns across matched experimental conditions.
  • When metastatic or lineage features are described, investigators commonly interpret results alongside morphology, passage history, and culture environment.

Common research applications

  • Cancer biology studies that compare proliferation-associated behavior, morphology, and pathway responses in vitro.
  • Assay development for treatment response, reporter monitoring, or phenotype comparison under matched culture conditions.
  • Side-by-side comparison of engineered versus parental background characteristics when relevant to the study design.

Changes in morphology, growth rate, viability, or reporter signal are typically interpreted together with passage history, culture matrix, and the specified growth conditions for the model.

Notes for experimental interpretation

  • Morphology, doubling behavior, and reporter or marker output can shift with passage number, substrate choice, and medium composition; these variables should be recorded alongside experimental readouts.
  • Matched controls such as parental cells, untreated cultures, or parallel cultures maintained under identical conditions help distinguish background effects from biology of interest.

Culture and product details

  • Growth Conditions: PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. Prigrow VIII Medium (TM018) + 10% FBS(Regular*) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂. *Do not heat-inactivate
  • Split Ratio: 1:2 to 1:8
🧊 Thawing Protocol
  1. Thaw cells quickly in a 37°C water bath while agitating gently (maximum 2 minutes). The vial cap should be kept above the water level to minimize the risk of contamination.
  2. Decontaminate the vial by spraying and wiping the exterior of the vial with 70% ethanol. From this point onwards, all operations should be strictly carried out inside a biological safety cabinet using aseptic conditions.
  3. Transfer the cell suspension into a 15ml sterile conical tube containing 5ml of pre-warmed, complete growth media. Centrifuge cells at 125xg for 5-7 minutes.
  4. Aspirate the supernatant without disturbing the cell pellet. Re-suspend the cell pellet in the recommended pre-warmed, complete growth media and dispense into a T25 culture flask.
  5. Incubate the cells at the recommended conditions.
🔬 Subculture Protocol
Volumes given below are for a T75 flask; proportionally increase or decrease the volume as required per culture vessel size. Subculture cells once the culture vessel is 80% confluent.
  1. Aspirate the culture media, and add 2-3ml of pre-warmed 0.25% Trypsin-EDTA to the culture vessel.
  2. Observe the cells under a microscope to confirm detachment (typically within 2-10 minutes). Cells that are difficult to detach can be put in 37°C, for several minutes to facilitate detachment.
  3. Neutralize Trypsin-EDTA by adding an equal volume of the complete growth media into the culture vessel.
  4. Transfer the culture suspension into a sterile centrifuge tube, and centrifuge at 125xg for 5 minutes. The actual centrifuge duration and speed may vary depending on the cell type.
  5. Aspirate the supernatant, and re-suspend the pellet with pre-warmed fresh complete growth media. Add appropriate aliquots of the cell suspension to new culture vessels, as desired.
  6. Incubate the cells at the recommended conditions.
How should I handle live cells once I receive them?
Please refer to our Cell Handling and Thawing Guidelines for detailed instructions on receiving, thawing, and culturing live cells:
https://www.abmgood.com/immortalized-cells-documents.html
Following these guidelines will help ensure optimal cell viability and performance.
Why are these cells classified as biosafety level II?
We follow the CDC-NIH recommendations that all mammalian sourced products should be handled at the Biological Safety Level 2 to minimize exposure of potentially infectious products. This information can be found in 'Biosafety in Microbiological and Biomedical Laboratories' (1999). Your institution's Safety Officer or Technical Services will be able to make the call as to whether BioSafety Level I is possible with these cells at your site, if desired.
What is your warranty or return policy?
Our warranty and return policy is outlined in abm’s Terms and Conditions, including details on product quality, limitations, and claims.
Please refer to the following link for full information:
https://www.abmgood.com/terms
For additional questions, our Order team is happy to assist and can be reached at order@abmgood.com.
How many times can cells divide?
The number of times cells can divide depends on the cell type:

Primary cells have a limited lifespan and will undergo a finite number of population doublings before entering senescence. The exact number varies by cell type and culture conditions.
Immortalized cell lines are capable of extended or indefinite proliferation under proper culture conditions, although growth characteristics may vary between lines.
Do I need Applied Cell Extracellular Matrix (G422) if I am using PriCoat™ flasks?
Please refer to the Growth Conditions section of your specific product page. This section will indicate whether Applied Cell Extracellular Matrix (G422), PriCoat™ flasks, or both are recommended for optimal cell attachment and growth, as requirements may vary by cell type.

Cell line sourcing and selection (species, tissue, and disease model matching) · Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA) · Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs) · Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles) · Inducible expression systems (Tet-On/Off and regulatable constructs) · Drug resistance marker selection (puromycin, G418, hygromycin, and others) · Custom growth and media optimisation for specific assay requirements · Scale-up production for high-throughput screening campaigns · Authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Talk to a Scientist or contact support@biohippo.com.

Julia K. Bar, Antonina Harłozińska.: Morphological and phenotypic characterization of a new established ovarian carcinoma cell line (OvBH-1.) Anticancer Res. 2000, Vol.20 no.5A; s.2975-2980

Julia K. Bar, Antonina Harłozińska, Sabine Kartarius, Mathias Montenarh, Ewa Wyrodek, Jan M. Rodriguez-Parkitna, Marian Kochman, Andrzej Ożyhar.: Temperature-sensitive ovarian carcinoma cell line (OvBH-1). Jpn.J.Cancer Res. 2002, 93, no.9; s.976-985.

Kamila Schlade-Bartusiak, Maria M. Sąsiadek, Julia K. Bar, Steffi Urbschat, Nikolaus Blin, Mathias Montenarh, Antonina Harłozińska-Szmyrka.: Cytogenetic and molecular cytogenetic characterization of the stable ovarian carcinoma cell line (OvBH-1) Cancer Genet.Cytogenet. 2006, 164, no.1; s.10-15

Julia K. Bar, Jolanta Saczko, Piotr Ziółkowski, Agnieszka Chwiłkowska, Iwona Słomska, Małgorzata Drąg-Zalesińska, Teresa Wysocka, Danuta Duś.: Photofrin II-based photosensitization of human ovarian clear-cell carcinoma cell line (OvBH-1). Pharmacol.Rep. 2007, 59, suppl.1; s.150-160

Jolanta Saczko, Iwona Kamińska, Małgorzata Kotulska, Julia Bar, Anna Choromańska, Nina Rembiałkowska, Katarzyna Bieżuńska-Kusiak, Joanna Rossowska, Danuta Nowakowska, Julita Kulbacka.: Combination of therapy with 5-fluorouracil and cisplatin with electroporation in human ovarian carcinoma model in vitro. Biomed. Pharmacother. 2014,.68, 5; s.573-580

Jolanta Saczko, Anna Choromańska, Nina Rembiałkowska, Magda Dubińska-Magiera, Iwona Bednarz-Misa, Julia Bar, Anna Marcinkowska, Julita Kulbacka.: Oxidative modification induced by photodynamic therapy with PhotofrinII and 2-methoxyestradiol in human ovarian clear carcinoma (OvBH-1) and human breast adenocarcinoma (MCF-7) cells Biomed. Pharmacother, 2015, 71,s,30-367.

Iwona Kamińska, Julia K. Bar.: The association between p53 protein phosphorylation at serine 15, serine 20 and sensitivity of cells isolated from patients with ovarian cancer and cell lines to chemotherapy in in vitro study. Pharmacol. Rep. 2018 Vol.70 no.3; s.570-576

Julia Bar, Piotr Grelewski, Iwona Deszcz, Leszek Noga, Lidia Hirnle, Anna Lis-Nawara.: Association between p53 protein phosphorylated at serine 20 expression and ovarian carcinoma stem cells phenotype: correlation with clinicopathological parameters of ovarian cancer. Neoplasma, 2019 Vol.66 no.5; s.801-809

Get a Quote

Please use this form for bulk quantity requests or customized products.

Contact Information

Product Information

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today